CTOs on the Move

Institute for Clinical Evaluative Sciences

www.ices.on.ca

 
Institute for Clinical Evaluative Sciences is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.ices.on.ca
  • 2075 Bayview Ave
    Toronto, ON CAN M4N 3M5
  • Phone: 416.480.6100

Executives

Name Title Contact Details

Similar Companies

Evelo Therapeutics

Evelo Therapeutics is the latest breakthrough microbiome company from Flagship VentureLabs, the innovation foundry of Flagship Ventures.

Provident Clinical Research and Consulting

Provident Clinical Research and Consulting, Inc. is a Bloomington, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

NOVOS

NOVOS develops science-based solutions to slow down human aging. NOVOS is a Public Benefit Corporation devoted to improving human longevity & health.

SeqOne Genomics

Introducing the most advanced platform for clinical genomic analysis… Solutions for each type of medical use Using data and machine learning to build a more accurate picture of each patient We are passionate about creating bioinformatic solutions that ...

Bamboo Therapeutics

Bamboo was formed to advance the work of Dr. Richard Jude Samulski, the Director of the Gene Therapy Center at the University of North Carolina (UNC), from the laboratory into human clinical trials where it could meet the requirements for drug approval. Dr. Samulski is a pioneer in the field of gene therapy. Over thirty (30) years ago, Dr. Samulski was the first person to realize the potential to use the adeno-associated virus (AAV) as a vehicle to replace a defective gene with a healthy gene. Since that time, he has re-engineered the naturally occurring virus to target delivery to certain tissues, de-target other tissues, and improve its safety. This has resulted in over twenty (20) patents related to the use of AAV for therapeutic uses. Dr. Samulski continues to lead innovation in the field of vector optimization and AAV re-engineering.